Editorial

Cognitive Improvement with Glutathione Supplement in Alzheimer’s Disease: A Way Forward

Pravat K. Mandal\textsuperscript{a,b,*}, Deepika Shukla\textsuperscript{a}, Manjari Tripathi\textsuperscript{c} and Lars Ersland\textsuperscript{d,e,f}

\textsuperscript{a}Neuroimaging and Neurospectroscopy Laboratory (NINS), National Brain Research Centre, Gurgaon, India
\textsuperscript{b}Florey Institute of Neuroscience and Mental Health, University of Melbourne Medical school campus, Melbourne, Australia
\textsuperscript{c}Department of Neurology, All Indian Institute of Medical Science, New Delhi, India
\textsuperscript{d}Department of Clinical Engineering, Haukeland University Hospital, Bergen, Norway
\textsuperscript{e}Department of Biological and Medical Psychology, University of Bergen, Norway
\textsuperscript{f}NORMENT Center of Excellence, Haukeland University Hospital, Norway

Accepted 10 January 2019

Abstract. Alzheimer’s disease (AD) is a devastating neurodegenerative disorder affecting millions of people worldwide. The actual cause of AD is still unknown. Oxidative stress is believed to be an important player in AD pathology. Glutathione (GSH) is a major antioxidant, and it is already known that GSH is depleted significantly in the hippocampal regions in mild cognitive impairment (MCI) and AD patients compared to healthy old subjects. Hence there is a serious discussion to improve the brain GSH level by supplementation. This editorial highlights the need for GSH supplementation for the cognitive enhancement in MCI and AD.

Alzheimer’s disease (AD) is a progressive neurodegenerative disorder manifested by cognitive deterioration, progressive impairment of activities of daily living, and behavioral disturbances \cite{1, 2}. Current conceptualization of AD presume that the neurodegenerative changes occur well before the clinical manifestations of the disease becomes apparent \cite{3}. With progressive neuronal degeneration, formation of neurofibrillary tangles and neurotic plaques gradually increases. As a result, it sets a threshold for the initiation of clinical symptoms of AD associated cognitive deficits which gradually worsen with time. The fundamental molecular etiology of neuronal loss resulting in cognitive decline in AD is still unknown. Although there are existing data to support amyloid \cite{4}, tau \cite{5}, oxidative stress \cite{6, 7}, membrane alternation \cite{8}, and soluble oligomeric amyloid-\textbeta{} (A\textbeta{}) \cite{9, 10} hypotheses, research in the clinical setting has indicated that oxidative stress plays an important role in the pathogenesis of AD \cite{11–14}. Oxidative stress is a general term used to describe the steady state level of oxidative damage in a cell, tissue, or organ, caused by the reactive oxygen species (ROS). ROS are chemically unstable and highly reactive, but their levels are kept relatively low by antioxidants (e.g., GSH, vitamin E & C, etc.). These facts underline the importance of an effective brain antioxidant system during the...
life span. Antioxidant strategies for AD include systematic treatment with vitamin C and E [15, 16], but results indicated that there were no significant clinical protective effects of vitamin E and C in dementia [17, 18].

Glutathione is a potent antioxidant and detoxifying agent that is produced de novo in the cytoplasm of every cell of the human body. The significant amount of GSH in the human brain are used for radical scavenging and balancing ROS. The intracellular brain antioxidant GSH interconverts into reduced GSH and GSSG, maintaining the ratio in most cells around 500:1 [19, 20]. Transgenic mice (which develop Aβ plaques throughout the cortex) show a significant decrease in GSH levels compared to wild type mice [21]. Studies in AD patients have shown that GSH metabolism is altered and regulated differently in male and female patients [22].

A recent study has shown that the depletion of GSH level in MCI and AD patients in the hippocampal regions is directly correlated with executive function using the Trail Making (B-A) test score [12]. Another study has demonstrated that intranasal administration of GSH elevates brain GSH levels in Parkinson’s disease (PD) patients [23]. However, to the best of our knowledge, no clinical trial has evaluated similar effects of GSH supplementation and its subsequent bioavailability in the brain tissue. There is no GSH trial available for AD patients, where GSH level in the brain were monitored non-invasively as well as behavioral studies in MCI patients. Hence, this editorial sensitizes the importance of GSH supplementation involving MCI patients to improve cognitive performance using peripheral supplements.

DETECTION OF GSH in vivo HEALTHY AND MCI/AD PATIENTS USING MR SPECTROSCOPY

Autopsy [27] as well as neuroimaging [13] studies have reported close association of the GSH distribution in human brain with gender, age, disease condition, and anatomical area. Glutathione can be detected in vivo selectively by the application of specialized pulse sequences [13, 32, 33]. GSH is distributed in various neuroanatomical regions of healthy subjects as well as patients with MCI and AD as reported using in vivo MRS studies [13]. Accordingly, healthy young brains showed higher GSH content and a specific GSH distribution pattern in various brain regions. The mean GSH content and distribution varied between male and female healthy subjects when compared between left frontal cortex (LFC) and right frontal cortex (RFC) [13]. It was reported that the reduction of GSH in both hippocampus and frontal cortices correlated (p < 0.001) with decline in cognitive functions [12]. Receiver operator characteristics analyses showed that hippocampal GSH depletion distinguish between MCI and elderly healthy controls with 87.5% sensitivity, 100% specificity, whereas cortical region GSH level differentiates MCI and AD with 91.7% sensitivity, 100% specificity [12]. The significant reduction in GSH selectively in the brain regions (frontal cortex and
hippocampus) affected by AD pathology, but not in the cerebellum of AD patients [12]. The autopsy studies indicated significant depletion of GSH level in cingulated cortex regions by 49% in AD subject. Moreover, this GSH depletion trend is found in MCI, and AD subjects from in vivo MR spectroscopic studies of frontal cortices and hippocampal regions [12, 13].

In another MRS study involving MCI subjects, it was found that GSH level increases with MCI compared to elderly control [34]. This increase in GSH level was explained as an early compensatory or neuroprotective response [34]. However, in the same study, the GSH peak was identified using PRESS pulse sequence in a 3T scanner where GSH peak appeared in close proximity of high intense choline peak. The probable anomaly of these results is due to the use of a PRESS sequence for detection of GSH. With this technique the GSH signal will be partly overlapped by intense signals arising from choline and creatine, thus complicating the accurate measurement of GSH. The MEGA-PRESS pulse sequence, on the other hand, is a very selective and confirmatory method to detect the GSH peaks. Hence, in any clinical trial involving GSH measurement, MRS with MEGA-PRESS should be the method of choice for AD clinical study with GSH [23].

VARIOUS TRIALS WITH GSH AND OTHER ANTIOXIDANTS

There are various clinical trials involving GSH to investigate GSH transportation across the intestinal epithelium [35], therapeutic effects of oral administration of glutathione in patients with non-alcoholic fatty liver disease [36], effect of oral GSH supplementation on changes in erythrocyte GSH level [37, 38]. The effect of GSH on anti-aging features (wrinkles in the skin) was also investigated [39, 40].

It was reported that GSH can be transported across the intestinal epithelium in an orally administered GSH in animal model study and the initial uptake of GSH into cells is reported as a rapid process [35]. The ingested GSH has potent nutraceutical benefits for human health to improve oxidative stress and defense in human [35]. The therapeutic effects of oral administration of GSH in patients with non-alcoholic fatty liver disease in open label, single arm, multi-center trial [36] indicated a significant decrease in alanine aminotransferase level as well as triglycerides, non-esterified fatty acids, and ferritin levels [36]. To determine the effect of oral GSH supplementation on erythrocyte GSH concentrations, including total reduced GSH, oxidized glutathione (GSSG), and their ratio in a randomized, double-blind, placebo-controlled clinical trial for 4 weeks on 40 healthy volunteers were conducted. Changes in erythrocyte GSH concentrations, including total GSH, oxidized glutathione (GSSG), and GSH: GSSG ratios were monitored. No significant changes in GSH concentrations in erythrocyte were observed [37]. In a long-term study, the effect of oral GSH supplementation on body stores of GSH in healthy adults, randomized, double-blinded, placebo-controlled trial GSH supplement for 6 months on 54 adults was conducted. GSH levels in blood increased after 1, 3, and 6 months versus baseline. At 6 months, mean GSH levels increased 30–35% in erythrocytes, plasma, and lymphocytes and 260% in buccal cells in the high-dose group. GSH levels increased 17% and 29% in blood and erythrocytes respectively, in the low-dose group. Natural killer cytototoxicity increased twofold in the high-dose group versus placebo [38]. This clearly demonstrates that study duration for oral GSH supplementation plays an important role for study outcome.

The orally administered GSH (500 mg per day for 4 weeks, on 60 healthy medical students) affects the skin melanin index, when compared with placebo in a randomized, double-blind, two-arm, placebo-controlled study. It was observed that melanin indices decreased consistently at two sites. Both GSH and placebo were very well tolerated. Oral GSH administration resulted in lightening of skin color [40]. In another similar type of study, to evaluate the influences of both GSH and oxidized form (GSSG) at doses lower than 500 mg/d, on improving skin properties, a randomized, double-blind, placebo-controlled study was conducted [39]. Oral GSH was administered for 12 weeks in 60 healthy volunteers, and skin features including melanin index, wrinkles, and other relevant biophysical properties were measured. Blood samples were collected for safety monitoring. GSH showed a significant reduction in wrinkles compared with those taking placebo. A tendency toward increased skin elasticity was observed in GSH compared with placebo. There were no serious adverse effects throughout the study [39].

A phase IIb randomized double blind, placebo controlled trial on 45 PD patients (Hoehn & Yahr stages 1-3) monitored the symptomatic relief effect of intranasal GSH supplement by administering 200 mg GSH thrice daily for three months. The subjects were observed over a one-month washout period. All cohorts of this study, including placebo showed
improvement during the intervention regime. However, as this study aimed at evaluating an appropriate trial design, conclusions regarding the superiority of GSH over placebo were not drawn [23].

To compare bioavailability, the effect on oxidative stress markers and the safety of a new sublingual form of GSH was studied with two commonly used dietary supplements: N-acetylcysteine (NAC) and oral GSH. In this randomized crossover study, sublingual GSH, oral GSH and NAC were administered for 3 weeks in 20 normal volunteers. Bioavailability, antioxidant efficacy, tolerance, reduced thiols, vitamin E, lipid status and adverse effects were monitored [41]. Significant superiority of a new sublingual form of GSH compared to both oral GSH and NAC, were observed. All the dosage forms were well tolerated and no adverse events were reported [41]. A nutraceutical formulation containing N-acetylcysteine among other compounds has shown some pro-cognitive benefits in AD and older adults, but the impact of NAC alone is less robust [42].

**ACKNOWLEDGMENTS**

Dr. Pravat Mandal (Principal Investigator) thanks the Department of Biotechnology, Ministry of Science and Technology, Government of India for funding this project (Grant no BT/Indo-Aus/10/31/2016/PKM) and acknowledges partial funding support from the Ministry of Information Technology, Govt. of India (DeitY/R&D/TDC/13(5)/2013 dated 20/12/2013). Financial support in the form of TATA INNOVATION AWARD (Award No.BT/HRD/01/05/2015) from the ministry of Science and Technology, Government of India is appreciated. Thanks to Ms. Divya Dwivedi, Project Assistant in the NINS lab (NBRC), for participating in literature search and Mr. Ritwick Mishra (Clinical Coordinator at NINS lab) for proof reading.

Authors’ disclosures available online (https://www.j-alz.com/manuscript-disclosures/18-1054r2).

**REFERENCES**


